GlassScriptPhysician profile
Joseph Yoo
NPI 1336568609
$7,815.57
in general payments reported to CMS, 2019-2025
39 companies · $1,724 in 2025
The $1,724 reported for 2025 was more than what 75% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $443 · 2020: $145 · 2021: $1,256 · 2022: $1,437 · 2023: $1,257 · 2024: $1,554 · 2025: $1,724.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,427 · Education: $108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,427.09 |
| Education | $107.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,084.96 | 2019-2025 | Linzess, Viberzi, Skyrizi |
| Janssen Biotech, INC. | $809.53 | 2021-2025 | Tremfya, Stelara, Remicade |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $784.24 | 2021-2025 | Xifaxan, Trulance, Plenvu |
| Takeda Pharmaceuticals U.S.A., INC. | $696.35 | 2020-2025 | Entyvio, Eohilia |
| Braintree Laboratories, INC. | $305.57 | 2021-2025 | Suflave, Sutab |
| Pfizer INC. | $273.95 | 2020-2025 | |
| Ferring Pharmaceuticals INC. | $265.81 | 2021-2025 | Rebyota, Clenpiq |
| Gilead Sciences, INC. | $257.85 | 2021-2025 | |
| Ardelyx, INC. | $223.07 | 2022-2024 | Ibsrela |
| Axonics, INC. | $221.39 | 2021-2023 | Axonics |
| Merck Sharp & Dohme LLC | $215.67 | 2019-2023 | Dificid, Zinplava |
| Redhill Biopharma INC. | $206.17 | 2020-2024 | Talicia |
| Qol Medical, LLC | $196.83 | 2024-2025 | Sucraid, Sucraid |
| Regeneron Healthcare Solutions, INC. | $190.32 | 2022-2025 | Dupixent |
| Phathom Pharmaceuticals, INC. | $174.59 | 2023-2025 | Voquezna |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $170.68 | 2023-2025 | |
| Celgene Corporation | $161.22 | 2021-2024 | Zeposia |
| Ironwood Pharmaceuticals, INC | $159.11 | 2021-2024 | Linzess |
| Celltrion USA INC. | $144.02 | 2025 | Vegzelma |
| Smith+Nephew, INC. | $142.07 | 2024 | Grafix Pl, Stravix Pl, Oasis |
| Lilly USA, LLC | $127.07 | 2024-2025 | Omvoh |
| Daiichi Sankyo INC. | $124.70 | 2019 | |
| Medical Device Business Services, INC. | $107.69 | 2024 | |
| Shockwave Medical, INC | $105.55 | 2025 | |
| Haemonetics Corporation | $95.80 | 2023 | Teg6s Hemostasis System |
| Boston Scientific Corporation | $95.25 | 2019 | |
| Madrigal Pharmaceuticals | $81.00 | 2024-2025 | Resmetirom, Rezdiffra |
| Covidien LP | $65.00 | 2019 | |
| Fujifilm Healthcare Americas Corporation | $59.86 | 2025 | |
| Teleflex LLC | $50.74 | 2025 | Guideliner |
| Aimmune Therapeutics, INC. | $42.37 | 2025 | Zenpep |
| Novo Nordisk INC | $37.61 | 2025 | Wegovy |
| Mahana Therapeutics, INC. | $27.88 | 2022 | |
| Abbott Laboratories | $23.73 | 2025 | Perclose Prostyle |
| Intercept Pharmaceuticals, INC. | $21.49 | 2025 | |
| Echosens North America, INC. | $19.33 | 2025 | Fibroscan |
| Janssen Pharmaceuticals, INC | $18.07 | 2021 | |
| Mauna Kea Technologies, INC. | $17.60 | 2021 | |
| Ucb, INC. | $11.43 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Yoo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.